Oliver A Cornely1, Rafael F Duarte2, Shariq Haider3, Pranatharthi Chandrasekar4, David Helfgott5, Javier López Jiménez6, Anna Candoni7, Issam Raad8, Michel Laverdiere9, Amelia Langston10, Nicholas Kartsonis11, Marlou Van Iersel12, Nancy Connelly13, Hetty Waskin13. 1. Department I of Internal Medicine, ZKS Köln, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany oliver.cornely@uk-koeln.de. 2. Department of Haematology, Catalan Institute of Oncology, Barcelona, Spain. 3. Juravinski Hospital, Hamilton, Ontario, Canada. 4. Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA. 5. Weill Cornell Medical College, New York, NY, USA. 6. Hospital Ramon y Cajal, Madrid, Spain. 7. University of Udine, Udine, Italy. 8. Department of Stem Cell Transplantation & Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA. 9. Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada. 10. Emory University, Atlanta, GA, USA. 11. MSD, North Wales, PA, USA. 12. MSD, Oss, Netherlands. 13. Merck & Co., Inc., Kenilworth, NJ, USA.
Abstract
BACKGROUND: Antifungal prophylaxis with a new oral tablet formulation of posaconazole may be beneficial to patients at high risk for invasive fungal disease. A two-part (Phase 1B/3) study evaluated posaconazole tablet pharmacokinetics (PK) and safety. METHODS: Patients with neutropenia following chemotherapy for haematological malignancy or recipients of allogeneic HSCT receiving prophylaxis or treatment for graft-versus-host disease received 300 mg posaconazole (as tablets) once daily (twice daily on day 1) for up to 28 days without regard to food intake. Weekly trough PK sampling was performed during therapy, and a subset of patients had sampling on days 1 and 8. Cmin-evaluable subjects received ≥6 days of dosing, and were compliant with specified sampling timepoints. Steady-state PK parameters, safety, clinical failure and survival to day 65 were assessed. ClinicalTrials.gov, NCT01777763; EU Clinical Trials Register, EUDRA-CT 2008-006684-36. RESULTS: Two hundred and ten patients received 300 mg posaconazole (as tablets) once daily. Among Cmin-evaluable subjects (n = 186), steady-state mean Cmin was 1720 ng/mL (range = 210-9140). Steady-state Cmin was ≥700 ng/mL in 90% of subjects with 5% (10 of 186) <500 ng/mL and 5% (10 of 186) 500-700 ng/mL. Six (3%) patients had steady-state Cmin ≥3750 ng/mL. One patient (<1%) had an invasive fungal infection. The most common treatment-related adverse events were nausea (11%) and diarrhoea (8%). There was no increase in adverse event frequency with higher posaconazole exposure. CONCLUSIONS: In patients at high risk for invasive fungal disease, 300 mg posaconazole (as tablets) once daily was well tolerated and demonstrated a safety profile similar to that reported for posaconazole oral suspension: most patients (99%) achieved steady-state pCavg exposures >500 ng/mL and only one patient (<1%) had a pCavg <500 ng/mL.
BACKGROUND: Antifungal prophylaxis with a new oral tablet formulation of posaconazole may be beneficial to patients at high risk for invasive fungal disease. A two-part (Phase 1B/3) study evaluated posaconazole tablet pharmacokinetics (PK) and safety. METHODS:Patients with neutropenia following chemotherapy for haematological malignancy or recipients of allogeneic HSCT receiving prophylaxis or treatment for graft-versus-host disease received 300 mg posaconazole (as tablets) once daily (twice daily on day 1) for up to 28 days without regard to food intake. Weekly trough PK sampling was performed during therapy, and a subset of patients had sampling on days 1 and 8. Cmin-evaluable subjects received ≥6 days of dosing, and were compliant with specified sampling timepoints. Steady-state PK parameters, safety, clinical failure and survival to day 65 were assessed. ClinicalTrials.gov, NCT01777763; EU Clinical Trials Register, EUDRA-CT 2008-006684-36. RESULTS: Two hundred and ten patients received 300 mg posaconazole (as tablets) once daily. Among Cmin-evaluable subjects (n = 186), steady-state mean Cmin was 1720 ng/mL (range = 210-9140). Steady-state Cmin was ≥700 ng/mL in 90% of subjects with 5% (10 of 186) <500 ng/mL and 5% (10 of 186) 500-700 ng/mL. Six (3%) patients had steady-state Cmin ≥3750 ng/mL. One patient (<1%) had an invasive fungal infection. The most common treatment-related adverse events were nausea (11%) and diarrhoea (8%). There was no increase in adverse event frequency with higher posaconazole exposure. CONCLUSIONS: In patients at high risk for invasive fungal disease, 300 mg posaconazole (as tablets) once daily was well tolerated and demonstrated a safety profile similar to that reported for posaconazole oral suspension: most patients (99%) achieved steady-state pCavg exposures >500 ng/mL and only one patient (<1%) had a pCavg <500 ng/mL.
Authors: Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Pierre Peterlin; Cécile Chauvin; Steven Le Gouill; Morgane Pere; Marie Dalichampt; Thierry Guillaume; Alice Garnier; Maxime Paré; Amandine Le Bourgeois; Philippe Moreau; Patrice Chevallier; Guillaume Deslandes; Thomas Gastinne Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Silke Gastine; William Hope; Georg Hempel; Ruta Petraitiene; Vidmantas Petraitis; Diana Mickiene; John Bacher; Thomas J Walsh; Andreas H Groll Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: Beatrice Mercorelli; Anna Luganini; Marta Celegato; Giorgio Palù; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191